Literature DB >> 18997164

Hepatic triacylglycerol accumulation and insulin resistance.

Cynthia A Nagle1, Eric L Klett, Rosalind A Coleman.   

Abstract

The association of hepatic steatosis with hepatic insulin resistance and type 2 diabetes has prompted investigators to elucidate the underlying mechanism. In this review we focus on pathways of lipid metabolism, and we review recent data, primarily from mouse models, that link lipid intermediates with insulin resistance. Most of the studies that implicate acyl-CoA, lysophosphatidic acid, phosphatidic acid, diacylglycerol, or ceramide rely on indirect associations. Convincing data to support the hypothesis that specific lipid intermediates initiate pathways that alter insulin signaling will require studies in which the concentration of each purported signaling molecule can be manipulated independently.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18997164      PMCID: PMC2674743          DOI: 10.1194/jlr.R800053-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  44 in total

Review 1.  Enzymes of triacylglycerol synthesis and their regulation.

Authors:  Rosalind A Coleman; Douglas P Lee
Journal:  Prog Lipid Res       Date:  2004-03       Impact factor: 16.195

Review 2.  Regulation of mTOR by phosphatidic acid?

Authors:  David A Foster
Journal:  Cancer Res       Date:  2007-01-01       Impact factor: 12.701

3.  PPAR-alpha-null mice are protected from high-fat diet-induced insulin resistance.

Authors:  M Guerre-Millo; C Rouault; P Poulain; J André; V Poitout; J M Peters; F J Gonzalez; J C Fruchart; G Reach; B Staels
Journal:  Diabetes       Date:  2001-12       Impact factor: 9.461

4.  Tissue-specific overexpression of lipoprotein lipase causes tissue-specific insulin resistance.

Authors:  J K Kim; J J Fillmore; Y Chen; C Yu; I K Moore; M Pypaert; E P Lutz; Y Kako; W Velez-Carrasco; I J Goldberg; J L Breslow; G I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-05       Impact factor: 11.205

5.  WY14,643, a peroxisome proliferator-activated receptor alpha (PPARalpha ) agonist, improves hepatic and muscle steatosis and reverses insulin resistance in lipoatrophic A-ZIP/F-1 mice.

Authors:  Chieh J Chou; Martin Haluzik; Charmaine Gregory; Kelly R Dietz; Charles Vinson; Oksana Gavrilova; Marc L Reitman
Journal:  J Biol Chem       Date:  2002-05-06       Impact factor: 5.157

6.  Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lep(ob)/Lep(ob) mice.

Authors:  Naoya Yahagi; Hitoshi Shimano; Alyssa H Hasty; Takashi Matsuzaka; Tomohiro Ide; Tomohiro Yoshikawa; Michiyo Amemiya-Kudo; Sachiko Tomita; Hiroaki Okazaki; Yoshiaki Tamura; Yoko Iizuka; Ken Ohashi; Jun-Ichi Osuga; Kenji Harada; Takanari Gotoda; Ryozo Nagai; Shun Ishibashi; Nobuhiro Yamada
Journal:  J Biol Chem       Date:  2002-03-28       Impact factor: 5.157

7.  Hepatic expression of malonyl-CoA decarboxylase reverses muscle, liver and whole-animal insulin resistance.

Authors:  Jie An; Deborah M Muoio; Masakazu Shiota; Yuka Fujimoto; Gary W Cline; Gerald I Shulman; Timothy R Koves; Robert Stevens; David Millington; Christopher B Newgard
Journal:  Nat Med       Date:  2004-02-08       Impact factor: 53.440

Review 8.  Synthesis and function of hepatic very-low-density lipoprotein.

Authors:  G F Gibbons; D Wiggins; A-M Brown; A-M Hebbachi
Journal:  Biochem Soc Trans       Date:  2004-02       Impact factor: 5.407

9.  Identification of an intracellular receptor for lysophosphatidic acid (LPA): LPA is a transcellular PPARgamma agonist.

Authors:  Thomas M McIntyre; Aaron V Pontsler; Adriana R Silva; Andy St Hilaire; Yong Xu; Jerald C Hinshaw; Guy A Zimmerman; Kotaro Hama; Junken Aoki; Hiroyuki Arai; Glenn D Prestwich
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-26       Impact factor: 11.205

10.  Stimulation of lipogenesis by pharmacological activation of the liver X receptor leads to production of large, triglyceride-rich very low density lipoprotein particles.

Authors:  Aldo Grefhorst; Baukje M Elzinga; Peter J Voshol; Torsten Plösch; Tineke Kok; Vincent W Bloks; Fjodor H van der Sluijs; Louis M Havekes; Johannes A Romijn; Henkjan J Verkade; Folkert Kuipers
Journal:  J Biol Chem       Date:  2002-07-03       Impact factor: 5.157

View more
  104 in total

1.  Comparison of the efficacy of liraglutide with pioglitazone on dexamethasone induced hepatic steatosis, dyslipidemia and hyperglycaemia in albino rats.

Authors:  K Vinodraj; I M Nagendra Nayak; J Vikram Rao; Paul Mathai; N Chandralekha; B Nitasha; D Rajesh; T K Chethan
Journal:  Indian J Pharmacol       Date:  2015 Mar-Apr       Impact factor: 1.200

2.  Pharmacological glycerol-3-phosphate acyltransferase inhibition decreases food intake and adiposity and increases insulin sensitivity in diet-induced obesity.

Authors:  Francis P Kuhajda; Susan Aja; Yajun Tu; Wan Fang Han; Susan M Medghalchi; Rajaa El Meskini; Leslie E Landree; Jonathan M Peterson; Khadija Daniels; Kody Wong; Edward A Wydysh; Craig A Townsend; Gabriele V Ronnett
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2011-04-13       Impact factor: 3.619

3.  MicroRNAs in hepatic pathophysiology in diabetes.

Authors:  Kirandeep Kaur; Himanshi Bhatia; Malabika Datta
Journal:  World J Diabetes       Date:  2011-10-15

Review 4.  Eicosanoids in metabolic syndrome.

Authors:  James P Hardwick; Katie Eckman; Yoon Kwang Lee; Mohamed A Abdelmegeed; Andrew Esterle; William M Chilian; John Y Chiang; Byoung-Joon Song
Journal:  Adv Pharmacol       Date:  2013

5.  Glycerol-3-phosphate acyltransferase 1 deficiency in ob/ob mice diminishes hepatic steatosis but does not protect against insulin resistance or obesity.

Authors:  Angela A Wendel; Lei O Li; Yue Li; Gary W Cline; Gerald I Shulman; Rosalind A Coleman
Journal:  Diabetes       Date:  2010-03-03       Impact factor: 9.461

6.  Modulation of lipid metabolism in glycyrrhizic acid-treated rats fed on a high-calorie diet and exposed to short or long-term stress.

Authors:  Hui Ping Yaw; So Ha Ton; Hsien-Fei Chin; Muhammad Kaiser Abdul Karim; Hamish Alexander Fernando; Khalid Abdul Kadir
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2015-03-20

7.  Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects.

Authors:  Faidon Magkos; Xiong Su; David Bradley; Elisa Fabbrini; Caterina Conte; J Christopher Eagon; J Esteban Varela; Elizabeth M Brunt; Bruce W Patterson; Samuel Klein
Journal:  Gastroenterology       Date:  2012-03-13       Impact factor: 22.682

8.  Aralia cordata inhibits triacylglycerol biosynthesis in HepG2 cells.

Authors:  Mun Ock Kim; Sun Hwa Lee; Jee Hee Seo; Il Soon Kim; Ah Reum Han; Dong Oh Moon; Sungchan Cho; Long Cui; Jungwoo Kim; Hyun Sun Lee
Journal:  J Med Food       Date:  2013-11-27       Impact factor: 2.786

9.  Inhibition of mitochondrial β-oxidation by miR-107 promotes hepatic lipid accumulation and impairs glucose tolerance in vivo.

Authors:  H Bhatia; B R Pattnaik; M Datta
Journal:  Int J Obes (Lond)       Date:  2015-10-26       Impact factor: 5.095

Review 10.  Aiming drug discovery at lysophosphatidic acid targets.

Authors:  Gabor Tigyi
Journal:  Br J Pharmacol       Date:  2010-09       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.